Mineralys (MLYS) | Financial Analysis & Statements
Mineralys Therapeutics Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-38.3M
Net Income
-32.2M
EPS (Diluted)
$-0.40
Balance Sheet Metrics
Total Assets
661.8M
Total Liabilities
15.1M
Shareholders Equity
646.7M
Debt to Equity
0.02
Cash Flow Metrics
Operating Cash Flow
-31.3M
Free Cash Flow
-37.9M
Revenue & Profitability Trend
Mineralys Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 132.0M | 168.6M | 70.4M | 26.2M | 16.3M |
| Selling, General & Administrative | 38.6M | 23.8M | 14.3M | 5.2M | 2.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 170.6M | 192.4M | 84.7M | 31.5M | 18.7M |
| Operating Income | -170.6M | -192.4M | -84.7M | -31.5M | -18.7M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 16.0M | 14.6M | 12.8M | 1.7M | - |
| Interest Expense | - | - | - | - | 27.0K |
| Other Non-Operating Income | - | 5.0K | 3.0K | 4.0K | -656.0K |
| Pre-tax Income | -154.7M | -177.8M | -71.9M | -29.8M | -19.4M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -154.7M | -177.8M | -71.9M | -29.8M | -19.4M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -170.5M | -192.4M | -84.7M | -31.5M | -18.7M |
| EPS (Basic) | - | $-3.66 | $-1.99 | $-0.76 | $-3.77 |
| EPS (Diluted) | - | $-3.66 | $-1.99 | $-0.76 | $-3.77 |
| Basic Shares Outstanding | - | 48539795 | 36188254 | 39056653 | 5152752 |
| Diluted Shares Outstanding | - | 48539795 | 36188254 | 39056653 | 5152752 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Mineralys Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 172.9M | 114.1M | 49.3M | 87.7M | 10.6M |
| Short-term Investments | 483.7M | 84.1M | 187.3M | 22.4M | 0 |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 4.8M | 7.2M | 12.5M | 2.7M | 510.0K |
| Total Current Assets | 661.4M | 205.4M | 249.1M | 112.8M | 11.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | - | - | - | - | - |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 382.0K | 499.0K | 102.0K | 1.6M | 3.0K |
| Total Non-Current Assets | 420.0K | 552.0K | 2.5M | 1.6M | 3.0K |
| Total Assets | 661.8M | 205.9M | 251.6M | 114.4M | 11.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.0M | 479.0K | 601.0K | 1.9M | 763.0K |
| Short-term Debt | - | - | - | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 15.1M | 14.6M | 10.5M | 8.1M | 5.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | - | - | - | - | - |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 158.6M | 29.0M |
| Total Liabilities | 15.1M | 14.6M | 10.5M | 166.7M | 34.0M |
| Equity | |||||
| Common Stock | 8.0K | 5.0K | 4.0K | 1.0K | 1.0K |
| Retained Earnings | -457.2M | -302.5M | -124.7M | -52.8M | -23.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 646.7M | 191.3M | 241.2M | -52.3M | -22.9M |
| Key Metrics | |||||
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Working Capital | 646.3M | 190.7M | 238.6M | 104.7M | 6.1M |
Balance Sheet Composition
Mineralys Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -154.7M | -177.8M | -71.9M | -29.8M | -19.4M |
| Depreciation & Amortization | 59.0K | 43.0K | 0 | - | - |
| Stock-Based Compensation | 19.3M | 11.3M | 5.1M | 455.0K | 80.0K |
| Working Capital Changes | -166.0K | 424.0K | -355.0K | 0 | 0 |
| Operating Cash Flow | -145.3M | -175.4M | -74.1M | -30.0M | -18.6M |
| Investing Activities | |||||
| Capital Expenditures | -15.0K | -96.0K | 0 | - | - |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -814.7M | -373.4M | -348.0M | -71.8M | 0 |
| Investment Sales | 425.0M | 488.5M | 187.5M | 50.0M | 0 |
| Investing Cash Flow | -389.8M | 115.0M | -160.5M | -21.8M | 0 |
| Financing Activities | |||||
| Share Repurchases | - | - | - | -1.6M | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 578.0M | 115.6M | 203.0M | 126.4M | 23.8M |
| Free Cash Flow | -142.4M | -166.4M | -81.2M | -29.2M | -14.6M |
| Net Change in Cash | 42.9M | 55.2M | -31.5M | 74.6M | 5.2M |
Cash Flow Trend
Mineralys Key Financial Ratios
Valuation Ratios
Forward P/E
-15.73
Price to Book
3.63
PEG Ratio
-15.73
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-36.91%
Return on Assets
-24.58%
Financial Health
Current Ratio
43.76
Debt to Equity
0.00
Beta
0.69
Per Share Data
EPS (TTM)
$-2.29
Book Value per Share
$7.93
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MLYS | 2.4B | - | 3.63 | -36.91% | 0.00% | 0.00 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






